A Phase 2 interventional study of VX-993 and HB/APAP in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated — none open to participants now, none under way, none of them phase 3. Acute Pain · Vertex Pharmaceuticals Incorporated.
Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, this one is the 3rd largest by enrollment, is the only one that started in 2024, is one of 5 in phase 2, and was the 8th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →None of the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated is open now. The open studies under Acute Pain, anywhere →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 367 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 262 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Acute Pain by Vertex Pharmaceuticals Incorporated, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
Key Inclusion Criteria:
Before Surgery:
After Surgery:
Key Exclusion Criteria:
Before Surgery:
After Surgery:
Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive different dose levels of VX-993.
Drug: VX-993 · Drug: Placebo (matched to HB/APAP)
Participants will be randomized to receive HB/APAP.
Drug: HB/APAP · Drug: Placebo (matched to VX-993)
Participants will be randomized to receive placebo matched to VX-993 and HB/APAP
Drug: Placebo (matched to VX-993) · Drug: Placebo (matched to HB/APAP)
Tablets for oral administration.
Drug pages: Hydrocodone · Acetaminophen
Capsules for oral administration.
Placebo matched to VX-993 for oral administration.
Placebo matched to HB/APAP for oral administration.
Time-weighted Sum of Pain Intensity Difference (SPID) as Recorded on the Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48)
Time frame: From 0 to 48 Hours After the First Dose of Study Drug
Proportion of Participants With Greater Than or Equal To (>=) 30 Percent (%) Reduction in NPRS at 48 Hours
Time frame: At 48 Hours After the First Dose of Study Drug
Proportion of Participants With >=50% Reduction in NPRS at 48 Hours
Time frame: At 48 Hours After the First Dose of Study Drug
Proportion of Participants With >=70% Reduction in NPRS at 48 Hours
Time frame: At 48 Hours After the First Dose of Study Drug
Maximum Observed Plasma Concentration (Cmax) of VX-993 and its Metabolite
Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-993 and its Metabolite
Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
Time to Reach Maximum Observed Plasma Concentration (Tmax) of VX-993 and its Metabolite
Time frame: Pre-dose to 12 Hours and 24 to 36 Hours After the First Dose of Study Drug
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 19
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in May 2025, 6 months.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VX-993
Vertex Pharmaceuticals Incorporated →